Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03591380 · ClinicalTrials.gov registry record · Phase 2
CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03591380 is a Phase 2 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 3 participants.
The verdict
NCT03591380, a Phase 2 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine whether kidney transplant recipients who receive belimumab (Benlysta®), combined with the standard of care medications for kidney transplant recipients, is safe and effective in helping prevent new donor specific antibodies (DSA) after transplantation. The presence of DSA increases the risk that the kidney transplant recipient's body will reject the new kidney. The investigators are doing this research because it is estimated that greater than 50% of kidney transplant failures are attributed to antibodies produced in the body, that attack the transplanted organ as a foreign object. DSA produced in the body after a kidney transplant, is thought to occur in 20-50% of patients and is associated with a low likelihood that the organ recipient's body will accept the new kidney. A major unmet need in the kidney transplant area are safe and effective therapies to prevent DSA after transplantation.
Interventions
- DRUG Belimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-05-14 |
| Est. Completion | 2021-12-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03591380
The ClinicalTrials.gov registry entry for NCT03591380 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Belimumab is the first listed.
NCT03591380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03591380 about?
NCT03591380 is a clinical study titled "CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients". The purpose of this research study is to determine whether kidney transplant recipients who receive belimumab (Benlysta®), combined with the standard of care medications for kidney transplant recipients, is safe and effective in helping prevent new donor specific antibodies (DSA) after transplantati...
What is the current status of trial NCT03591380?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2019-05-14. Estimated completion is 2021-12-03.
What interventions are being tested in trial NCT03591380?
The interventions under investigation include: Belimumab (DRUG).
Who is sponsoring clinical trial NCT03591380?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.